Xinqiang Huang
YOU?
Author Swipe
View article: Supplementary Figure 2S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 2S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Expression levels of miR-17 TuD. The data are expressed as delta CT value normalized to GAPDH.
View article: Supplementary Figure 3S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 3S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Inhibition of miR-17 family by miR-17 TuD had no effect on caspase 3/7 activity. Caspase 3/7 activity was represented as relative activity compared to NC TuD expression cells.
View article: Supplementary Methods and legends from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Methods and legends from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Supplementary Methods and Figure legends
View article: Data from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Data from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Hepatocellular carcinoma (HCC) is one of the most common human malignancies with poor prognosis and urgent unmet medical need. Aberrant expression of multiple members of the miR-17 family are frequently observed in HCC, and their overexpre…
View article: Supplementary Methods and legends from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Methods and legends from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Supplementary Methods and Figure legends
View article: Supplementary Figure 4S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 4S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
MetaCoreTM schematic of the TGF-β signaling pathway showing genes regulated by miR-17 TuD in Hep3B (1) and HepG2 (2).
View article: Supplementary Figure 2S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 2S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Expression levels of miR-17 TuD. The data are expressed as delta CT value normalized to GAPDH.
View article: Supplementary Figure 1S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 1S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Inhibition of miR-17, 20a, 20b, 93 and 106b activity by miR-17 TuD in HeLa cells as determined by luciferase reporter assays.
View article: Data from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Data from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Hepatocellular carcinoma (HCC) is one of the most common human malignancies with poor prognosis and urgent unmet medical need. Aberrant expression of multiple members of the miR-17 family are frequently observed in HCC, and their overexpre…
View article: Supplementary Figure 3S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 3S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Inhibition of miR-17 family by miR-17 TuD had no effect on caspase 3/7 activity. Caspase 3/7 activity was represented as relative activity compared to NC TuD expression cells.
View article: Supplementary Figure 1S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 1S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
Inhibition of miR-17, 20a, 20b, 93 and 106b activity by miR-17 TuD in HeLa cells as determined by luciferase reporter assays.
View article: Supplementary Figure 4S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Supplementary Figure 4S from Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth Open
MetaCoreTM schematic of the TGF-β signaling pathway showing genes regulated by miR-17 TuD in Hep3B (1) and HepG2 (2).
View article: Molecular characterization of a precision-cut rat lung slice model for the evaluation of antifibrotic drugs
Molecular characterization of a precision-cut rat lung slice model for the evaluation of antifibrotic drugs Open
The translation of novel pulmonary fibrosis therapies from preclinical models into the clinic represents a major challenge demonstrated by the high attrition rate of compounds that showed efficacy in preclinical models but demonstrated no …
View article: Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds
Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds Open
Precision-cut liver tissue slice (PCLS) contains all major cell types of the liver parenchyma and preserves the original cell-cell and cell-matrix contacts. It represents a promising ex vivo model to study liver fibrosis and test the antif…
View article: Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC)
Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC) Open
Hepatocellular carcinoma (HCC) remains a significant clinical challenge with few therapeutic options. Genomic amplification and/or overexpression of the MYC oncogene is a common molecular event in HCC, thus making it an attractive target f…